Abstract
Parkinsonism constitutes a set of clinical signs and symptoms characterized by bradykinesia and tremor at rest and / or rigidity. The main etiology is Parkinson's disease (PD), but there are other causes such as atypical parkinsonism. The vast majority of PD cases are sporadic, however, there is a minority where the etiology is due to an inherited mutation, either autosomal dominant (AD), autosomal recessive (RA), or X-linked inheritance. Identifying these heritable causes is important for proper genetic counseling and treatment. We present the case of a patient with early-onset PD where an AD mutation in the GIGYF2 gene (PARK11) was identified. We subsequently present a brief review of the literature.
References
Reich SG, Savitt JM. Parkinson disease. Med Clin North Am. 2019;103(2):337-50. https://doi.Org/10.1016/j.mcna.2018.10.014.
Arredondo-Blanco K, Zerón-Martínez R, Rodríguez-Violante, Cervantes-Arriaga A. Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción. Gaceta Med Mex. 2018;154:719-26. https://doi.org/10.24875/GMM.18003702.
Chaudhuri KR, Jenner P. Two hundred years since James Parkinsons essay on the shaking palsy - Have we made progress? Insights from the james parkinsons 200 years course held in London. Mov Disord. 2017;32: 1311-15. https://doi.org/10.1002/mds.27104.
McDonald C, Gordon G, Hand A, Walker RW, Fisher JM. 200 years of Parkinson's disease: what have we learnt from James Parkinson? Age Ageing. 2018;47(2):209-14. https://doi.org/10.1093/ageing/afx196.
Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Wein-traub D, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264-310. https://doi.org/10.1002/mds.27115.
Martínez-Fernández R, Gasca-Salas C, Sánchez-Ferro A, Obeso JA. Actualización en la enfermedad de Parkinson. Rev Med Clin Condes. 2016;27:363-79.
Payne K, Walls B, Wojcieszek J. Approach to assessment of Parkinson disease with emphasis on genetic testing. Med Clin North Am. 2019;103(6):1055-75. https://doi.org/10.1016/j.mcna.2019.08.003.
Sheerin UM, Houlden H, Wood NW Advances in the genetics of Parkinson's disease: a guide for the clinician. Mov Disord Clin Pract. 2014;1(1):3-13. https://doi.org/10.1002/mdc3.12000.
Saavedra Moreno J, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurol Colomb. 2019;35(3 Supl 1):2-10.
Duque AF, Lopez J, Hernández H, Benítez B, Yunis J, Fernández W, Arboleda H, Arboleda G. Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's disease patients. Colomb Med. 2015; 46(3):117-21.
Infante CA, Mora Forero LM, Ortega Rojas JC, Arboleda-Bustos CE, Fernández W, Arboleda H, Arboleda G. Análisis de mutaciones en los genes PINK1 y PARKIN en pacientes colombianos con enfermedad de Parkinson. Nova. 2014;12(21):15-21.
Pineda-Trujillo N, Dulcey Cepeda A, Arias Pérez W, Moreno Masmela S, Saldarriaga Henao A, Sepúlveda Falla D, et al. Una mutación en el gen PARK2 causa enfermedad de Parkinson juvenil en una extensa familia colombiana. Iatreia. 2009;22(2):122-31.
Pineda-Trujillo N, Carvajal-Carmona LG, Buritica O, Moreno S, Uribe C, Pineda D, et al. A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia. Neurosci Lett. 2001;298:87-90.
Tipton PW, Jaramillo-Koupermann G, Soto-Beasley AI, Walton RL, Soler- Rangel S, Romero-Osorio O, et al. Genetic characterization of Parkinson's disease patients in Ecuador and Colombia. Parkinsonism Relat Disord. 2020;75:27-29. https://doi.org/10.1016/j.parkreldis.2020.05.005.
Vélez-Pardo C, Lorenzo-Betancor O, Jiménez-del-Río M, Moreno S, Lopera F, et al. The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism Relat Disord. 2019; 63:204-8. https://doi.org/10.1016/j.parkreldis.2019.01.030.
Pineda-Trujillo N, Apergi M, Moreno S, Arias W, Lesage S, Franco A, et al. A genetic cluster of early onset Parkinson's disease in a Colombian population. Am J Med Genet B Neuropsychiatr Genet. 2006;141:885-9.
Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, Brice A, Smith RJ. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008;82(4):822-33. https://doi.org/10.1016/j.ajhg.2008.01.015.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T; Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124-35. https://doi.org/10.1086/341282.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T; Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12(20):2599-608. https://doi.org/10.1093/hmg/ddg270.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T; Parkinson Study Group. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72(4):1053-7. https://doi.org/10.1086/374383.
Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease - repurposed drugs and new approaches. Nat Rev Neurol. 2019;15(4):204-23. https://doi.org/10.1038/s41582-019-0155-7.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.